Industry

USFDA gives nod for Diclofenac Sodium topical solution

Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s) and the same has been approved by USFDA

The Health Master

December 4, 2022

170

Last Updated on October 2, 2024 by The Health Master

Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), diclofenac sodium topical solution USP, 2% w/w.

The ANDA was filed by Aleor Dermaceuticals Limited (Aleor) which was amalgamated with Alembic.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pennsaid topical solution, 2% w/w, of Horizon Therapeutics Ireland DAC (Horizon).

Click for more articles on USFDA

Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s). Refer to our label for full indication.

Aleor had previously received tentative approval for this ANDA.

Diclofenac sodium topical solution USP, 2% w/w has an estimated market size of US$ 512 million for twelve months ending September 2022 according to IQVIA.

Alembic has received a cumulative total of 177 ANDA approvals (154 final approvals and 23 tentative approvals) from the USFDA.

Other drugs approval by USFDA

USFDA gives approval for Venlafaxine ER tablets

USFDA gives nod for Levothyroxine Sodium For Injection

USFDA gives nod for Nifedipine ER tablets

USFDA gives nod for Amphotericin B Liposome Injection

USFDA gives approval for Potassium-deficiency drug

USFDA gives final approval for Cyclophosphamide capsules

Also read

IPC releases amendment list for IP 2022, details here

NPPA releases 2nd list with draft ceiling prices for 43 formulations

USFDA gives approval for Venlafaxine ER tablets